Alexander Labrunerie & CO. Inc. Has $1.21 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Alexander Labrunerie & CO. Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 45,777 shares of the biopharmaceutical company’s stock after buying an additional 681 shares during the period. Alexander Labrunerie & CO. Inc.’s holdings in Pfizer were worth $1,214,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the third quarter valued at $35,000. Joseph Group Capital Management raised its stake in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at $43,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PFE shares. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 1.2 %

Pfizer stock opened at $25.88 on Wednesday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market cap of $146.64 billion, a PE ratio of 34.97, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The firm’s 50-day simple moving average is $26.27 and its 200 day simple moving average is $27.82. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.